SEOM guidelines on hydroelectrolytic disorders

Clin Transl Oncol. 2014 Dec;16(12):1051-9. doi: 10.1007/s12094-014-1234-2. Epub 2014 Oct 11.

Abstract

Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneoplastic syndrome, we must not forget that very often, these disorders could be caused by various drugs, including some of the antineoplastic agents most frequently used, such as platin derivatives or some biologics. These guidelines review major management of diagnosis, evaluation and treatment of the most common alterations of sodium, calcium, magnesium and potassium in cancer patients. Aside from life-sustaining treatments, we have reviewed the role of specific drug treatments aimed at correcting some of these disorders, such as intravenous bisphosphonates for hypercalcemia or V2 receptor antagonists in the management of syndrome of inappropriate antidiuretic hormone secretion-related hyponatremia.

Publication types

  • Practice Guideline

MeSH terms

  • Humans
  • Neoplasms / complications*
  • Paraneoplastic Syndromes / diagnosis*
  • Paraneoplastic Syndromes / therapy
  • Water-Electrolyte Imbalance / diagnosis*
  • Water-Electrolyte Imbalance / etiology
  • Water-Electrolyte Imbalance / therapy